Binx health announced that it has received CE approval for its chlamydia and gonorrhea home test and has submission for an FDA clearance


STI test from home in 30 minutes (Credit: binx health)

A new chlamydia and gonorrhea home test determining the presence and treatment of sexually transmitted infections (STIs) within 30 minutes can now be used from home, reducing the spread of infection.

Situated in Trowbridge, UK, binx health received European CE marking for its multiplex test, which delivers laboratory quality results based on the company’s “easy-to-use io diagnostic system” –  a rapid molecular diagnostic platform.

Jeffrey Luber, binx’s CEO, said: “Modern healthcare delivery requires tools that meet consumers’ needs where they live, work and shop.

“Doing this effectively means delivering fast, accurate, cost-effective solutions at brick-and-mortar locations, as well as physician-ordered, medical guideline-based testing online, that work to bring consumers from ‘worry to well’ in the locations most convenient for them.

“Through scientific rigour, guideline-based testing, and an ‘anywhere’ mind-set that puts the consumer at the centre of all we do, today we embark on a path to deliver omnichannel, high quality care in family health, starting with young people and STIs as our launching point.”


How does the binx chlamydia and gonorrhea home test work?

chlamydia and gonorrhea home test

Most male STI tests require a urine or blood sample (Credit: Health)More than one million STIs are acquired worldwide every day, with chlamydia and gonorrhoea representing two of the most prevalent.

Latest statistics from Public Health England show that rates of STIs in England remain high, with a young person is diagnosed with a case of chlamydia or gonorrhoea every four minutes.

In 2017, there were 420,000 diagnoses of STIs in England, and chlamydia accounted for nearly half of them. There were also more than 44,000 diagnoses of gonorrhoea.

Similarly, in the US, infection rates have risen an astonishing 67% since 2013, with 20 to 24-year-olds most affected.

According to the World Health Organization, a person can have an STI without having obvious symptoms of disease, and infections can also be spread through non-sexual means such as via blood or blood products.

Common symptoms of STIs include vaginal discharge, urethral discharge or burning in men, genital ulcers, and abdominal pain.

With its digital approach, binx aims to eliminate the increasing financial pressures healthcare professionals are under to improve efficiency, while maintaining a patient-centred approach to care with its io system, which is capable of detecting a broad range of infectious diseases.

The majority of chlamydia and gonorrhoea tests are sent to central laboratories, with a week-long waiting period from first visit to treatment.

This can result in  patients continuing to spread infection, and 40% of positive patients never returning for treatment.

The binx io system is positioned to radically change this paradigm, as it enables non-laboratory-trained users to run a test with the same accuracy as a central lab test in just 30 minutes, creating a new model for “test-and-treat” care.

The diagnostic system consisting of disposable cartridges (io cartridge), is expected to significantly improve patient outcomes due to its capability to avoid delays in treatment and unnecessary follow-up appointments.

Binx’s chief medical officer Dr Howard Heller said: “Achieving a 30-minute diagnostic turnaround time for two of the most common STIs is a major public health breakthrough.

“Rapid results equal rapid, appropriate treatment. This new panel enables a path to
not just same day, but same visit testing and treatment, eliminating an immense barrier to care and cure.”

The firm said that its platform allows patients and consumers to leave a retail pharmacy, primary care office, urgent care facility, and any other physical location with treatment in hand during a single visit.

Although the multiplex test has not been cleared for use in the US, the company recently completed its multi-centre clinical study for submission to FDA for clearance under its 510(k) regulatory pathway.